MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that it has received a notice of allowance from the Chinese Patent Office for a new patent which covers MN-001 . The allowed claims cover the compound as a polymorphic form of MN-001 , pharmaceutical compositions, and manufacturing processes.